首页> 外文OA文献 >Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: One-year follow-up
【2h】

Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: One-year follow-up

机译:改良曲安奈德制剂治疗难治性糖尿病性黄斑水肿后路巩膜后输注:一年随访

摘要

PURPOSE. To evaluate prospectively the efficacy and safety of posterior juxtascleral infusion of a new formulation of triamiabetic macular edema (DME) represents the major cause of decreased visual acuity in diabetic patients. Approxi-cinolone acetonide for refractory diffuse diabetic macular dema. ETHODS. This was an interventional case series. Twenty-two consecutive eyes of 18 patients with refractory diffuse diabetic macular edema were included in the study. Each patient un- derwent a complete ophthalmic examination, including optical coherence tomography (OCT) and digital fluorescein angiography (FA). All patients received a suspension of 40 mg triamcinolone acetonide, 20 mg sodium chondroitin sulfate, and 15 mg sodium hyaluronate (1.5 mL), delivered posteriorly through a conjunctival and Tenon's incision. All patients completed the 1-year follow-up. ESULTS. On average, studied eyes received 1.5 treatments. Mean preoperative foveal thickness (±SD) and visual acuity (±SD) were 474.2±136.6 μm and 0.6±0.37 logarithm of the inimum angle of resolution (logMAR), respectively. The central foveal thickness was significantly reduced from baseline at every follow-up visit (P 0.001). Mean (±SD) reductions in acular thickness were 136±108 μm at 1 week and 128±122 μm after 1 year of follow-up. Mean (±SD) improvement in isual acuity at 12 months was 0.15±0.21 logMAR (P .008). Visual acuity improvement of one or more lines and three or more lines were observed in 14 (63.6%) and 6 (27.3%) eyes, respectively. Seven eyes (31.8%) required topical treatment due to a significant intraocular pressure increase. ONCLUSIONS. Posterior juxtascleral infusion of a new formula- tion of triamcinolone acetonide is an effective treatment for diffuse diabetic macular edema unresponsive to conventional grid laser photocoagulation. A randomized, larger study is warranted. © Association for Research in Vision and Ophthalmology.
机译:目的。前瞻性评估后三角巩膜后输注新配方的三形性黄斑水肿(DME)的疗效和安全性是糖尿病患者视力下降的主要原因。扑热息痛丙酮用于难治性弥漫性糖尿病性黄斑脱膜。 ETHODS。这是一个介入病例系列。该研究包括18例难治性弥漫性糖尿病性黄斑水肿患者的22只连续眼睛。每位患者都接受了全面的眼科检查,包括光学相干断层扫描(OCT)和数字荧光血管造影(FA)。所有患者均接受40 mg曲安奈德,20 mg硫酸软骨素钠和15 mg透明质酸钠(1.5 mL)的混悬液,这些混悬液通过结膜和Tenon切口向后递送。所有患者均完成了1年的随访。结果。平均而言,研究的眼睛接受了1.5次治疗。术前平均中央凹厚度(±SD)和视敏度(±SD)分别为最大分辨角(logMAR)的对数474.2±136.6μm和0.6±0.37对数。每次随访时中心凹中央厚度均较基线明显降低(P 0.001)。眼厚度平均减少(±SD)在第1周为136±108μm,在随访1年后为128±122μm。 12个月时平均视力改善(±SD)为0.15±0.21 logMAR(P .008)。在14只眼(63.6%)和6只眼(27.3%)中,分别观察到一条或多条线和三条或更多线的视力提高。由于眼内压显着增加,七只眼(31.8%)需要局部治疗。结论。后向巩膜后输注新配方的曲安奈德是一种有效的治疗弥漫性糖尿病性黄斑水肿的方法,对常规的栅格激光光凝反应无反应。有必要进行一项更大的随机研究。 ©视觉和眼科研究协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号